Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim F Greten

Showing results (11-20 of 222) with videos related to

Pageof 23
Sort By:
NEJM Evidence|February 6, 2024
Two Milestone Studies in Liver Cancer ImmunotherapyTim F Greten, Cecilia Monge
Journal of Hepatology|August 21, 2022
Interventional radiology meets immuno-oncology for hepatocellular carcinomaRiad Salem, Tim F Greten
European Journal of Gastroenterology & Hepatology|February 1, 2003
CD40 in hepatocellular carcinoma: relevant or not?Tim F Greten, Michael Ott
Science Immunology|July 25, 2017
Commensal bacteria (ab)use CD8<sup>+</sup> T cells to induce insulin resistanceChi Ma, Tim F Greten
Cancer Journal (Sudbury, Mass.)|March 23, 2023
The Microbiome and Liver CancerYuta Myojin, Tim F Greten
Journal of Hepatology|July 13, 2010
Radiofrequency ablation for the treatment of HCC--maybe much more than simple tumor destruction?Tim F Greten, Firouzeh Korangy
Gut|November 3, 2016
Shall we blame CD4 T cells for everything?Tim F Greten, Firouzeh Korangy
Journal of Leukocyte Biology|June 3, 2016
Editorial: "Invisible" MDSC in tumor-bearing individuals after antibody depletion: fact or fiction?Chi Ma, Tim F Greten
Digestion|June 13, 2017
Current Standard and Future Perspectives in Non-Surgical Therapy for Hepatocellular CarcinomaTobias Eggert, Tim F Greten
Cancer Medicine|December 21, 2023
Underrepresentation of Hispanics in clinical trials for liver cancer in the United States over the past 20 yearsCecilia Monge, Tim F Greten
Pageof 23

Showing results (11-20 of 222) with videos related to

Sort By:
Pageof 23
NEJM Evidence|February 6, 2024
Two Milestone Studies in Liver Cancer ImmunotherapyTim F Greten, Cecilia Monge
Journal of Hepatology|August 21, 2022
Interventional radiology meets immuno-oncology for hepatocellular carcinomaRiad Salem, Tim F Greten
European Journal of Gastroenterology & Hepatology|February 1, 2003
CD40 in hepatocellular carcinoma: relevant or not?Tim F Greten, Michael Ott
Science Immunology|July 25, 2017
Commensal bacteria (ab)use CD8<sup>+</sup> T cells to induce insulin resistanceChi Ma, Tim F Greten
Cancer Journal (Sudbury, Mass.)|March 23, 2023
The Microbiome and Liver CancerYuta Myojin, Tim F Greten
Journal of Hepatology|July 13, 2010
Radiofrequency ablation for the treatment of HCC--maybe much more than simple tumor destruction?Tim F Greten, Firouzeh Korangy
Gut|November 3, 2016
Shall we blame CD4 T cells for everything?Tim F Greten, Firouzeh Korangy
Journal of Leukocyte Biology|June 3, 2016
Editorial: "Invisible" MDSC in tumor-bearing individuals after antibody depletion: fact or fiction?Chi Ma, Tim F Greten
Digestion|June 13, 2017
Current Standard and Future Perspectives in Non-Surgical Therapy for Hepatocellular CarcinomaTobias Eggert, Tim F Greten
Cancer Medicine|December 21, 2023
Underrepresentation of Hispanics in clinical trials for liver cancer in the United States over the past 20 yearsCecilia Monge, Tim F Greten
Pageof 23